REGENXBIO Reports 23% Revenue Growth to $29.7 Million in Q3 2025

REGENXBIO Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company generated total revenues of $29.7 million for the third quarter, a 23% increase from $24.2 million in the same period last year. This growth was primarily driven by a substantial rise in service revenue, which surged to $6.1 million from just $0.2 million, largely due to development services provided under the collaboration with Nippon Shinyaku. However, license and royalty revenue saw a slight decline, dropping to $23.6 million from $24.0 million, attributed to a decrease in royalties from Zolgensma, which reported lower sales.

In terms of operating expenses, REGENXBIO's total costs decreased to $82.1 million from $86.3 million year-over-year, reflecting a reduction in the cost of license and royalty revenues. Research and development expenses rose slightly to $56.1 million, up from $54.4 million, driven by increased personnel costs and manufacturing-related expenses for lead product candidates. General and administrative expenses also increased to $20.3 million from $19.4 million, primarily due to higher professional services and consulting costs. The net loss for the quarter was $61.9 million, compared to a loss of $59.6 million in the prior year.

The company’s balance sheet showed total assets of $525.2 million as of September 30, 2025, up from $466.0 million at the end of 2024. This increase was supported by cash and cash equivalents of $58.8 million and marketable securities totaling $215.4 million. Notably, REGENXBIO's accumulated deficit grew to $1.06 billion, reflecting ongoing investments in research and development and the challenges of transitioning to profitability.

Strategically, REGENXBIO has made significant strides in its collaborations, particularly with AbbVie and Nippon Shinyaku. The company received a $110 million upfront payment from Nippon Shinyaku in March 2025, contributing to its revenue growth. Additionally, the company is actively engaged in multiple clinical trials for its gene therapy candidates, including ABBV-RGX-314 and RGX-121, with plans for pivotal trials and potential regulatory submissions in the near future.

Looking ahead, REGENXBIO anticipates continued investment in its product development pipeline, with expectations of incurring significant research and development expenses. The company has indicated that its current cash reserves are sufficient to fund operations for at least the next 12 months, but it will need to secure additional capital to support its long-term growth and commercialization efforts. The outlook remains contingent on the successful development and regulatory approval of its product candidates, as well as the ability to generate revenue from collaborations and licensing agreements.